Ipca Laboratories (NSE:IPCALAB) Other Stockholders Equity: ₹80,384 Mil (As of Mar. 2026)


NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
91 GF Score
Price ₹1,762.40
GF Value ₹1,600.85
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ipca Laboratories Other Stockholders Equity?

Ipca Laboratories NSE:IPCALAB -1.71% 91 Other Stockholders Equity is ₹80,384 Mil as of Mar. 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 91/100 and a GF Value™ of ₹1,600.85 (Fairly Valued). The stock has 5 warning signs investors should review.

Ipca Laboratories's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹80,384 Mil.

Ipca Laboratories's quarterly Other Stockholders Equity declined from Sep. 2025 (₹74,015 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹80,384 Mil).

Ipca Laboratories's annual Other Stockholders Equity declined from Mar. 2024 (₹13,107 Mil) to Mar. 2025 (₹12,950 Mil) but then increased from Mar. 2025 (₹12,950 Mil) to Mar. 2026 (₹80,384 Mil).

Ipca Laboratories Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories Other Stockholders Equity Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,056.00 13,158.60 13,106.90 12,949.70 80,384.40

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,949.70 0.00 74,015.30 0.00 80,384.40
NSE:IPCALAB
91GF Score
Ipca Laboratories Ltd NSE:IPCALAB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipca Laboratories Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹80,384 Mil mean?
Ipca Laboratories (NSE:IPCALAB) has a Other Stockholders Equity of ₹80,384 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ipca Laboratories and its competitors.
Is Ipca Laboratories' Other Stockholders Equity too high?
Ipca Laboratories' current Other Stockholders Equity is ₹80,384 Mil. Overall, Ipca Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Other Stockholders Equity compare to ZTS and UTHR?
Ipca Laboratories' Other Stockholders Equity of ₹80,384 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ipca Laboratories and its competitors. Ipca Laboratories's current Other Stockholders Equity is ₹80,384 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,600.85, compared to a current price of ₹1,762.40 — trading 10.1% above its estimated fair value. The current Other Stockholders Equity is ₹80,384 Mil. Ipca Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Other Stockholders Equity is ₹80,384 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,762.40 is trading 10.1% above its estimated GF Value™ of ₹1,600.85. GuruFocus considers Ipca Laboratories to be Fairly Valued.

Key valuation signals for NSE:IPCALAB:

  • Other Stockholders Equity: ₹80,384 Mil
  • GF Value™: ₹1,600.85 vs. price of ₹1,762.40 (10.1% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
91GF Score

Get the complete analysis for NSE:IPCALAB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,762.40
Price
₹1,600.85
GF Value